Infliximab biosimilar - Celltrion

Drug Profile

Infliximab biosimilar - Celltrion

Alternative Names: Anti-TNF alpha Mab; Anti-TNF alpha monoclonal antibody; CT-P13; Inflectra; Infliximab biosimilar - Hospira; Infliximab BS; infliximab-dyyb; Remsima

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Celltrion
  • Developer Alvogen; Celltrion; Hospira; Nippon Kayaku; Orion
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 17 Feb 2017 Safety and efficacy data from a phase III trial in Crohn's disease released by Celltrion
  • 15 Feb 2017 Celltrion and Pfizer complete a phase III trial in Crohn's disease in Belgium, Hungary, the Netherlands, Italy, Romania, Spain, Denmark, United Kingdom and USA (NCT02096861) (EudraCT2013-004497-10)
  • 17 Oct 2016 Launched for Ankylosing spondylitis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top